Czech/SlovakiaCzech RepublicSlovakia

EU brings Czech bio-hub to life

07.03.2012

The Czech government has beefed up its investments in biotech with the help of EU structural funds. In February, the country’s Education Minister Josef Dobes gave the go-ahead for the Biocev centre in Vestec near Prague. Although the EU has cut the proposed budget by 30%, the joint project set up by the Czech Academy of Science and the Charles University Prague will receive enough money to build a biomedical research hub within the next two years. “Despite the almost 30% cut in the originally requested subsidy, we have managed to pass from intentions to a real project, while maintaining high quality and intertwined expert programmes,” said Vaclav Horejsi, Director of the Institute of Molecular Genetics at the Czech Academy of Sciences. About 600 researchers will work at the €91.4m bio­medical hub, which aims to boost its research programmes in drug development, diagnostics, and regenerative medicine by luring world-class scientists with high wages and moving expenses. Biocev is one of six so-called ‘Centres of Excellence’ that will be funded with a total budget of €834m of EU money. On the biotech side they include the Brno-based €100m centre CEITEC and the International Clinical Research Centre FNUSA-ICRC, which costs around €200m.

Czech/SlovakiaCzech RepublicSlovakia

11.11.2008

Prague/Tokyo – Tokyo-based Otsuka Pharmaceutical has established its first research, development and manufacturing facility in Eastern Europe. By the end of August, the diversified company had completed the acquisition of Czech...

Czech/SlovakiaCzech RepublicSlovakia

22.08.2008

Prague – Czech scientists have appealed to the European Council not to to politicise the approval process for biotech crops. “Although the EU has the strictest rules on GM plants in the world, politicians in Brussels prefer to...

Czech/SlovakiaCzech RepublicSlovakia

16.07.2008

Brno – Czech biotechnologists and EU industry experts have worked out an action plan to improve the development of industrial biotechnology in the Czech Republic. The recommendations are based on three SWOT analyses (R&D,...

Czech/SlovakiaCzech RepublicSlovakia

20.05.2008

Bratisava – German Lanxess, specialist for the development, manufacture and distribution of specialty chemicals and intermediates, has opened a new sales company for Central/Eastern Europe in Bratislava. This is its 3rd...

Czech/SlovakiaCzech RepublicSlovakia

20.05.2008

Prague – Gate2biotech has released a report on what’s going on in biotechnology in the Czech Republic. Windows-users can download a free electronic copy of the company registry and academic landscape or order a hardcopy at:...

Czech/SlovakiaCzech RepublicSlovakia

19.03.2008

Prague – The worldwide clinical research organisation Icon plc (Dublin, Ireland) has further expanded its activities in Eastern Europe. The CRO opened offices in Prague (Czech Republic), Kiev (Ukraine), and Bucharest (Romania),...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Prague – The Czech Republic has increased its R&D expenditures significantly in the last year. At a1.88 billion, R&D investments rose by 18% compared to 2005, the second largest increase world-wide. Those expenditures achieved...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Kourim/Basel – Lonza Biotec s.r.o. (Kourim, Czech Republic), a specialist for microbial fermentation and manufacturing services, has completed the extension of its production plant in Kourim designed for the cGMP-compliant...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Prague – Prague Clinical Services s.r.o. will conduct the pivotal phase III trials in Europe for Gia­conda Ltd.’s (Sydney, Australia) lead product Myoconda®, an anti­biotic combination therapy for the treatment of MAP infection...

Czech/SlovakiaCzech RepublicSlovakia

24.09.2007

Prague/Norwood – The international clinical trial company Medpace Inc. (Norwood, USA) has acquired the Czech contract research organisation Monax s.r.o. (Prague) for an undisclosed sum. With the acquisition, which the firm...

Displaying results 21 to 30 out of 70

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-czech-slovakia/browse/2/article/eu-brings-czech-bio-hub-to-life.html

Stock list

All quotes

TOP

  • SERODUS (N)3.05 NOK7.02%
  • SUMMIT (UK)4.03 GBP3.87%
  • DEINOVE (F)13.32 EUR2.46%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ALMIRALL (E)11.07 EUR-7.13%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • CELLECTIS (F)13.54 EUR112.6%
  • ADDEX (CH)4.54 CHF108.3%

FLOP

  • THROMBOGENICS (B)8.51 EUR-51.5%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-42.9%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 13.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events